Abstract | BACKGROUND: METHODS: Between August 2001 and March 2003 19 patients were eligible to enter. Gemcitabine was administered as a 30-minutes infusion at a dosage of 1 g/m2 on day 1, 8 and 15 every 4 weeks. All patients had progressive disease during (n = 12) or shortly after an anthracycline-based regimen (n = 3). RESULTS: Four of 19 patients did not start study treatment because of fulminant progression. Fifteen patients with a median age 47 years (32-72) were assessable. All patients had received at least one prior treatment regimen (range, 1-6) for metastatic disease containing anthracyclines (n = 15) and ifosfamide (n = 11). To date, a total of 72+ cycles have been applied (median; 3, 1-28+). Seven patients (47%) had progressive disease after completion of two cycles at the first response assessment. One patient (6%) attained a partial remission, and 7 patients (47%) achieved disease stabilisations. One patient is still on treatment after more than 2.5 years. The calculated progression-free rate at 3 and 6 months was 46.7% (CI(95%), 21.4-71.9) and 13.3% (CI(95%), (0-30.5). 95% of the cycles have been applied without any dose modification or treatment delay. CONCLUSIONS: Considering response and progression-free rate as the primary endpoints for phase II trials in pretreated STS, gemcitabine has moderate efficacy.
|
Authors | J T Hartmann, K Oechsle, J Huober, A Jakob, M Azemar, M Horger, L Kanz, C Bokemeyer |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 24
Issue 3
Pg. 249-53
(May 2006)
ISSN: 0167-6997 [Print] United States |
PMID | 16133789
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antimetabolites, Antineoplastic
- Deoxycytidine
- Gemcitabine
|
Topics |
- Adult
- Aged
- Antimetabolites, Antineoplastic
(adverse effects, therapeutic use)
- Deoxycytidine
(adverse effects, analogs & derivatives, therapeutic use)
- Disease-Free Survival
- Female
- Humans
- Male
- Middle Aged
- Sarcoma
(drug therapy)
- Soft Tissue Neoplasms
(drug therapy)
- Gemcitabine
|